Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

15.29
+0.40002.69%
Post-market: 15.00-0.2900-1.90%18:55 EDT
Volume:5.40M
Turnover:81.84M
Market Cap:1.50B
PE:-2.62
High:15.52
Open:14.79
Low:14.43
Close:14.89
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:1.30
T/O Rate:6.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-5.17
PE(LYR):-2.62

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH)

TIPRANKS
·
Yesterday

US Stocks on the MOVE-Halozyme, Moderna, Merck

Reuters
·
Yesterday

Ultragenyx Gains on $210 Million US FDA Voucher Sale

Reuters
·
Oct 07

Ultragenyx Pharmaceutical - Under Deal with U.S. Department of Health Co to Pay 20% of Prv Sale Proceeds to Nih - SEC Filing

THOMSON REUTERS
·
Oct 07

Ultragenyx Pharmaceutical - Enters Agreement to Sell Priority Review Voucher for $210 Mln

THOMSON REUTERS
·
Oct 07

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

THOMSON REUTERS
·
Oct 07

Ultragenyx Pharmaceutical (RARE) Could Be 42% Undervalued On EMA Filing Progress

Simply Wall St.
·
Oct 03

Ultragenyx Pharmaceutical - Receives FDA Approval for Rebisufligene Etisparvovec on Sept 17, 2026

THOMSON REUTERS
·
Oct 02

Ultragenyx Pharmaceutical - Announces Ema Validation of Maa for Rebisufligene Etisparvovec Gene Therapy

THOMSON REUTERS
·
Oct 02

Ultragenyx Says EMA Validates MAA for MPS IIIA Gene Therapy Rebisufligene Etisparvovec

Reuters
·
Oct 02

Ultragenyx call volume above normal and directionally bullish

TIPRANKS
·
Sep 24

Movement Alert|Ultragenyx Pharmaceutical Rises 9.39% in Regular Trading, FDA Approval of Fayuvi Gene Therapy Continues to Fuel Rally

Market Focus
·
Sep 23

Ultragenyx Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Ultragenyx price target raised to $20 from $18 at Morgan Stanley

TIPRANKS
·
Sep 18

U.S. Stocks on the MOVE-CoreWeave, StubHub, Ultragenyx

Reuters
·
Sep 18

Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 18

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 18

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18